KPIs & Operating Metrics(New)
Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Amortization - IntangiblesConsolidated Net IncomeCost of RevenueEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Gross ProfitIncome from Continuing OperationsIncome from Non-Controlling InterestsIncome towards Parent CompanyInterest & Investment IncomeInterest ExpensesNet Income towards Common StockholdersOperating ExpensesOperating IncomeOther Operating ExpensesProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)
Others
Ratios

Adaptive Biotechnologies (ADPT) EBT (2018 - 2025)

Historic EBT for Adaptive Biotechnologies (ADPT) over the last 8 years, with Q3 2025 value amounting to $9.5 million.

  • Adaptive Biotechnologies' EBT rose 12973.8% to $9.5 million in Q3 2025 from the same period last year, while for Sep 2025 it was -$79.6 million, marking a year-over-year increase of 5925.41%. This contributed to the annual value of -$159.6 million for FY2024, which is 2916.46% up from last year.
  • As of Q3 2025, Adaptive Biotechnologies' EBT stood at $9.5 million, which was up 12973.8% from -$25.6 million recorded in Q2 2025.
  • Over the past 5 years, Adaptive Biotechnologies' EBT peaked at $9.5 million during Q3 2025, and registered a low of -$69.5 million during Q4 2023.
  • Over the past 5 years, Adaptive Biotechnologies' median EBT value was -$47.5 million (recorded in 2024), while the average stood at -$44.1 million.
  • Per our database at Business Quant, Adaptive Biotechnologies' EBT plummeted by 7293.68% in 2023 and then skyrocketed by 12973.8% in 2025.
  • Adaptive Biotechnologies' EBT (Quarter) stood at -$61.4 million in 2021, then surged by 34.53% to -$40.2 million in 2022, then tumbled by 72.94% to -$69.5 million in 2023, then skyrocketed by 51.46% to -$33.7 million in 2024, then soared by 128.31% to $9.5 million in 2025.
  • Its EBT stands at $9.5 million for Q3 2025, versus -$25.6 million for Q2 2025 and -$29.8 million for Q1 2025.